Results 161 to 170 of about 44,162 (208)

A multi-center cross-sectional investigation of <i>BRAF</i> V600E mutation in Ameloblastoma. [PDF]

PeerJ
Tun KM, Lapthanasupkul P, Iamaroon A, Thosaporn W, Klanrit P, Kintarak S, Thanasan S, Srimaneekarn N, Kitkumthorn N.   +8 more
europepmc   +1 more source

Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins. [PDF]

Oncogene
Fernández-Pisonero I, Lorenzo-Martín LF, Drosten M, Santos E, Barbacid M, Alarcón B, Bustelo XR.   +6 more
europepmc   +1 more source

Oncogenic KRAS addiction states differentially influence MTH1 expression and 8-oxodGTPase activity in lung adenocarcinoma. [PDF]

Redox Biol
Mateo-Victoriano B, Samaranayake GJ, Pokharel S, Sahayanathan GJ, Jayaraj C, Troccoli CI, Watson DC, Mohsen MG, Guo Y, Kool ET, Rai P.   +10 more
europepmc   +1 more source

Exploring the Role of BCL2 Interactome in Cancer: A Protein/Residue Interaction Network Analysis. [PDF]

Biology (Basel)
Ilyas S, Lee D.
europepmc   +1 more source

MTHFD2 promotes esophageal squamous cell carcinoma progression via m6A modification‑mediated upregulation and modulation of the PEBP1‑RAF1 interaction. [PDF]

Int J Mol Med
Zhou H, Gong H, Zeng X, Zeng C, Liu D, Liu J, Zhang Y.   +6 more
europepmc   +1 more source

FGR Src family kinase causes signaling and phenotypic shift mimicking retinoic acid-induced differentiation of leukemic cells. [PDF]

Oncotarget
Kazim N, Peng W, Yue J, Yen A.
europepmc   +1 more source

Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report. [PDF]

Hum Vaccin Immunother
Zhang Q, Li L, Qian X.
europepmc   +1 more source

Pathogenesis and Management Strategies in Radioiodine-Refractory Differentiated Thyroid Cancer: From Molecular Mechanisms Toward Therapeutic Approaches: A Comprehensive Review. [PDF]

J Clin Med
Voinea IA, Petrova E, Dumitru N, Cocoloș A, Ioachim D, Goldstein AL, Ghemigian AM.   +6 more
europepmc   +1 more source

Melanoma genomics - will we go beyond BRAF in clinics? [PDF]

J Cancer Res Clin Oncol
Mirek J, Bal W, Olbryt M.
europepmc   +1 more source

Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis. [PDF]

PLoS One
Kang D, Li J, Li Y, Xu J, Yang J, Zhang Z.   +5 more
europepmc   +1 more source